Clinical Outcomes of COVID-19 Convalescent Plasma According to Treatment Timing and ELISA Antibody Levels: A Real-World Retrospective Cohort Study.

Özlem Bayraktar Saral, Ayla Yavuz, Şenol Ardıç, Tuncay Yazıcı, Serap Özer Yaman

Abstract read

In one paragraph

Article in Medicina (Kaunas, Lithuania), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Özlem Bayraktar SaralDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Trabzon Kanuni Training and Research Hospital, Trabzon University, Trabzon 61335, Türkiye.

Ayla YavuzBlood Center, Trabzon Kanuni Training and Research Hospital, Trabzon University, Trabzon 61335, Türkiye.

Şenol ArdıçDepartment of Emergency Medicine, Faculty of Medicine, Trabzon Kanuni Training and Research Hospital, Trabzon University, Trabzon 61335, Türkiye.ORCID 0000-0003-3621-7327

Tuncay YazıcıDepartment of Emergency Medicine, Bayburt State Hospital, Bayburt 69000, Türkiye.ORCID 0000-0001-5119-6515

Serap Özer YamanDepartment of Medical Biochemistry, Faculty of Medicine, Trabzon Kanuni Training and Research Hospital, Trabzon University, Trabzon 61335, Türkiye.ORCID 0000-0002-5089-0836

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, ViralCOVID-19AdultAgedCohort StudiesCOVID-19 SerotherapyEnzyme-Linked Immunosorbent AssayFemaleHumansImmunization, PassiveImmunoglobulin GMaleMiddle AgedRetrospective StudiesSARS-CoV-2Time FactorsAntibodies, ViralImmunoglobulin Gantibody levelconvalescent plasmaCOVID-19ELISA indexmortalitypassive immunotherapytreatment timing

Identifiers

PMID42796256

DOI10.3390/medicina62091649

PMCPMC13609586

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.